1CDC. Update: swine influenza A/HIN1 infections-California and Texas, April 2009 [ J ]. MMWR Morb Mortal Wkly Rep, 2009,58:435-437.
2CDC. Swine influenza A/H1N1 infection in two children- Southern California, March- April 2009 [ J ]. MMWR Morb Mortal Wkly Rep,2009,58:400-402.
3World Health Organization. New influenza A/H1N1 virus: global epidemiological situation,June 2009[ J]. Wkly Epidemiol Rec ,2009,84:249-257.
4CDC. Use of influenza A/H1N1 2009 monovalent vaccine: recommendations of the Advisory Committee on Immunization Practices ( ACIP), 2009 [ J ]. MMWR Recomm Rep, 2009,58(RR- 10) :1-8.
5CDC. Serum cross-reactive antibody response to a novel influenza A/H1N1 virus after vaccination with seasonal influenza vaccine[J]. MMWR Morb Mortal Wkly Rep,2009,58:521-524.
6European Committee for Proprietary Medicinal Products. Guideline on dossier structure and content for pandemic influenza vaccine marketing authorisation application (CPMP/ VEG/ 4717/03). European Agency for the Evaluation of Medicinal Products[ EB/OL]. [ 2008- 12- 18 ]. http://www.emea. europa. eu/Ddfs/human/vwp/471703enfin. pdf.
7Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: clinical data needed to support the licensure of pandemic influenza vaccines [ EB/OL ]. [ 2007- 05- 01 ]. http ://www. fda. gov/cber/guidelines.htm.
8GREENBERG M E, LAI M H, HARTEL G F, et al. Response after one dose of a monovalent influenza A ( H1N1 ) 2009 vaccine-preliminary report [ J ]. N Engl J Med, 2009 [ Epub ahead of print].
2TO K K, HUNG 1 F, LI L W, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic Ht Nl 2009 influenza virus infection [ J]. Clin Infect Dis, 2010, 50(6) : 850 -859.
3NQUYEN H T, TRUJILLO A A, SI-IEU T G, et al. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States[J]. Antivira Res, 2012, 93(3): 381 -386.
4LUKE T C, KILBANE E M, JACKSON J L, et al. Meta- analy- sis: convalescent blood products for spanish influenza pneumonia: a future HsN1 treatment? [J]. Ann Intern Med, 2006, 145(8) : 599 - 609.
5HUNG I F, TO K K, LEE C K, et al. Convalescent plasma trent- ment reduced mortality in patients with severe pandemic influenza A(H5N1)2009 virus infection[J]. Clin Infect Dis, 2011, 52 (4) : 447 -456.
6AOKI F Y, HAYDEN F G, DOLIN R. Antiviral drugs ( other than antiretrovirals) [ M]// MANDELL G L, BENNETT J E, DOLIN R, et al. Principlesand Practices of Infectious Diseases. 7th ed. New York: Churchill Livingstone Elsevier, 2009.
7CHAN K H, TO K K, HUNG I F, et al. Differences in antibody responses of individuals with natural infection and those vaccinated against pandemic H1 N1 2009 influenza [ J]. Clin Vaccine Immu- nol, 2011, 18(5) : 865' -873.
8WICHMANN O, STOCKER P, POGGENSEE G, et al. Pandemic influenza A (H1 N1 ) 2009 breakthrough infections and estimates of vaccine effectiveness in Germany 2009-2010 [ J]. Euro Surveill, 2010, 15(18): 19561.
9HUNG I F, TO K K, LEE C K, et al. Effect of clinical and viro- logical parameters on the level of neutralizing antibody against pan- demic influenza A virus Hl N1 2009 [ J ]. Clin Infect Dis, 2010, 51 (3) : 274 - 279.
10ZHOU B, ZHONG N S, GUAN Y. Treatment with convalescent plasma for influenza A ( H5 N1 ) infection [ J ]. N Engl J Med, 2007, 357(14) : 1450 - 1451.
